ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,63
0,11%
Bitcoin
59 287,31
1,80%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 4D Molecular Therapeutics Inc (FDMT)

  7. 4D Molecular Therapeutics Inc (FDMT) Actualités

FDMT 4D Molecular Therapeutics Inc

26,38
0,99 (3,90%)
Après les heures de négociation
Dernière mise à jour : 22:56:17
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
4D Molecular Therapeutics Inc FDMT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,99 3,90% 26,38 22:56:17
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
25,31 24,93 26,54 26,38 25,39
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202414:00GLOBE4DMT Announces Presentations at ARVO 2024 Annual Meeting
28/3/202413:00GLOBE4DMT Announces Update on Regulatory Interactions and..
04/3/202414:00GLOBE4DMT to Participate in Upcoming Investor Conferences
01/3/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202422:12EDGAR2Form 8-K - Current report
29/2/202422:05GLOBE4DMT Reports Full Year 2023 Financial Results and..
21/2/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202403:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202402:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202414:00GLOBE4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2..
09/2/202422:56EDGAR2Form 8-K - Current report
08/2/202422:50EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
08/2/202402:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202401:42EDGAR2Form 3/A - Initial statement of beneficial ownership of..
07/2/202405:27GLOBE4D Molecular Therapeutics Announces Pricing of Upsized..
05/2/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/2/202422:35EDGAR2Form S-3ASR - Automatic shelf registration statement of..
05/2/202422:05GLOBE4D Molecular Therapeutics Announces Proposed Public Offering..
03/2/202423:00GLOBE4DMT Presents Positive Interim Data from Randomized Phase 2..
29/1/202414:00GLOBE4DMT to Host Corporate Webcast to Discuss Interim Data from..
25/1/202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202422:50EDGAR2Form 144 - Report of proposed sale of securities
23/1/202414:00GLOBE4DMT Receives Rare Pediatric Disease Designation from FDA..
08/1/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:49EDGAR2Form 144 - Report of proposed sale of securities
04/1/202423:48EDGAR2Form 144 - Report of proposed sale of securities
04/1/202414:30EDGAR2Form 8-K - Current report
04/1/202414:00GLOBE4DMT Highlights Recent Clinical Pipeline Progress, Near-Term..
03/1/202414:01GLOBE4DMT and Arbor Biotechnologies Establish Partnership to..
21/12/202318:31DJN4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
21/12/202314:00GLOBE4DMT Receives FDA Regenerative Medicine Advanced Therapy..
18/12/202323:16EDGAR2Form 144 - Report of proposed sale of securities
15/12/202323:24EDGAR2Form 144 - Report of proposed sale of securities
13/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202314:00GLOBE4DMT to Present Interim 24 Week Data from Randomized Phase 2..
22/11/202322:20EDGAR2Form 8-K - Current report
15/11/202314:00GLOBE4DMT to Participate in Upcoming Investor Conferences
09/11/202322:23EDGAR2Form 8-K - Current report
09/11/202322:19GLOBE4DMT Reports Third Quarter 2023 Financial Results and..
01/11/202321:00GLOBE4DMT Presents Positive Interim Data from Phase 1/2 AEROW..

Dernières Valeurs Consultées

NASDAQ
FDMT
4D Molecular Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés